Sorrento Gets FDA Go-Ahead to Launch Phase I Study for Nose Drops Against COVID-19

Retrieved on: 2021-03-03 17:26:15

Tags for this article:

Click the tags to see associated articles and topics

Sorrento Gets FDA Go-Ahead to Launch Phase I Study for Nose Drops Against COVID-19. View article details on hiswai:

Excerpt

The monoclonal antibody was discovered from its G-MAB library. CD47 is a glycoprotein ubiquitously expressed in a range of cancers and plays a ...

Article found on: www.biospace.com